Loading clinical trials...

COMPLETEDPHASE2

Eltrombopag for Treatment of Fanconi Anemia

An Open-label, Phase II Study to Assess the Efficacy and Safety of Eltrombopag for the Treatment of Children and Adolescents With Fanconi Anemia.

NCT06045052•Julian Sevilla

View on ClinicalTrials.gov

Summary

An open-label, phase II study to assess the efficacy and safety of eltrombopag for the treatment of children and adolescents with Fanconi anemia.

Detailed Description

Open-label, phase II study to assess the efficacy and safety of eltrombopag in the treatment of patients diagnosed with Fanconi anemia who have no immediate curative treatment for their bone marrow failure (n=10). The primary objective of this open-label, phase II proof of concept study is to assess the efficacy and safety of using eltrombopag for the treatment of patients with FA before conducting a larger phase II/III study. Specific objectives: * Primary: To assess the efficacy of eltrombopag on hematopoiesis by measuring changes in peripheral platelet, hemoglobin and neutrophil counts. * Secondary: To assess the safety of eltrombopag in patients with Fanconi anemia. If the preliminary efficacy and safety results from the study are positive, we will propose its expansion to a multi-institutional Phase II/III study within the framework of the Spanish Fanconi Anemia Research Network.

Eligibility

Age

4 - 17 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with a diagnosis of Fanconi anemia. Diagnosis will be defined by the presence of biallelic mutations in genes known to cause the disease and/or by positive chromosome breakage analysis of lymphocytes and/or skin fibroblasts (for cases of mosaicism).
•Age from 4 to ≤ 17 years.
•Lansky index \> 80%.
•Informed consent provided in accordance with current legislation.
•Presenting with one or more of one of the following clinically significant cytopenias:
•platelet count ≤ 50x109/L or transfusion dependence, having required at least 2 transfusions in the 8 weeks prior to inclusion in the study; granulocyte count \< 0.75x109/L; hemoglobin \< 9 gr/dL or transfusion-dependent anemia having received 2 transfusions in the 8 weeks prior to inclusion in the study.

Exclusion Criteria

•Patients with HLA-matched related donor or unrelated donor with a 12/12 match who is immediately available.
•Evidence of myelodysplastic syndrome or leukemia or cytogenetic abnormalities predictive of these disorders in bone marrow aspirates. In the event, the evaluations performed two months before patient inclusion in the clinical study will be considered valid.
•Baseline creatinine greater than 2.5 times the upper limit of normality.
•GOT/AST or GPT/ALT more than three times the upper limit of normality. Direct bilirubin greater than 1.5 times the upper limit of normality.
•Patients who are already receiving treatment with some drug for bone marrow failure may be included as long as the dose administered remains stable for at least two months. In the event that such treatment requires an increase in dose during the study, the patient must withdraw from the trial. Patients who have already started Revolade® treatment in the previous two months may also be included, and the blood counts and baseline bone marrow studies performed at the start of treatment will be used.
•Women of postpubertal age and therefore at risk of pregnancy should have a negative serum or urine pregnancy test at the screening visit and agree to use a contraceptive method throughout the treatment period and for at least one month after.

Locations (1)

Hospital Infantil Universitario Niño Jesús (HIUNJ)

Madrid, Spain

Key Dates

Start Date

December 2, 2020

Primary Completion Date

June 19, 2023

Completion Date

August 29, 2023

Last Updated

September 21, 2023

Enrollment

ACTUAL participants

Conditions

Fanconi Anemia

Interventions

Eltrombopag

DRUG

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

View study

RECRUITINGPHASE2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830

Fanconi AnemiaSevere Marrow Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 21, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Eltrombopag for Treatment of Fanconi Anemia

Inclusion Criteria

Exclusion Criteria

Familial Investigations of Childhood Cancer Predisposition

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Prenatal Transplantation for Fetuses With Fanconi Anemia

Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts

Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia